Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis

References

• Vedamurthy A, Ananthakrishnan AN. Influence of environmental factors in the development and outcomes of inflammatory bowel disease. Gastroenterol Hepatol. 2019;15:72–82.
   Google Scholar
• Shen ZH, Zhu CX, Quan YS, et al. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24:5–14.
   PubMed Web of Science ®Google Scholar
• Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145:16–27.
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.
   PubMed Web of Science ®Google Scholar
• Boal Carvalho P, Cotter J. Mucosal healing in ulcerative colitis: a comprehensive review. Drugs. 2017;77:159–173.
   PubMed Web of Science ®Google Scholar
• Lemmens B, Arijs I, Van Assche G, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1194–1201.
   PubMed Web of Science ®Google Scholar
• Kevans D, Kirsch R, Dargavel C, et al. Histological markers of clinical relapse in endoscopically quiescent ulcerative colitis. Inflamm Bowel Dis. 2020 Oct 23;26(11):1722–1729.
   Google Scholar
• Battat R, Duijvestein M, Guizzetti L, et al. Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Am J Gastroenterol. 2019;114:733–745.
   PubMed Web of Science ®Google Scholar
• DeRoche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:178–192.
   PubMedGoogle Scholar
• Dinallo V, Marafini I, Di Fusco D, et al. Neutrophil extracellular traps sustain inflammatory signals in ulcerative colitis. J Crohns Colitis. 2019;13:772–784.
   PubMed Web of Science ®Google Scholar
• Sumagin R, Brazil JC, Nava P, et al. Neutrophil interactions with epithelial-expressed ICAM-1 enhances intestinal mucosal wound healing. Mucosal Immunol. 2016;9:1151–1162.
   PubMed Web of Science ®Google Scholar
• Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612–619.
   PubMed Web of Science ®Google Scholar
• Wéra O, Lancellotti P, Oury C. The dual role of neutrophils in inflammatory bowel diseases. J Clin Med. 2016;5:118.
   Web of Science ®Google Scholar
• Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2510–2517.
   Google Scholar
• Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–1270.
   PubMed Web of Science ®Google Scholar
• Heller F, Florian P, Bojarski C, et al. Interleukin-13 Is the key effector th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564.
   PubMed Web of Science ®Google Scholar
• Rampal R, Wari N, Singh AK, et al. Retinoic acid is elevated in the mucosa of patients with active ulcerative colitis and displays a proinflammatory role by augmenting IL-17 and IFNγ production. Inflamm Bowel Dis. 2020. DOI:https://doi.org/10.1093/ibd/izaa121.
   Google Scholar
• Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut. 2009;58:1629–1636.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Panés J, Khurana S, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015;64:894–900.
   PubMed Web of Science ®Google Scholar
• Danese S, Rudzinski J, Brandt W, et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015;64:243–249.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–1214.
   PubMed Web of Science ®Google Scholar
• Low D, Nguyen DD, Mizoguchi E. Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther. 2013;7:1341–1357.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A. Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci. 2012;105:263–320.
   PubMed Web of Science ®Google Scholar
• Glymenaki M, Singh G, Brass A, et al. Compositional changes in the gut mucus microbiota precede the onset of colitis-induced inflammation. Inflamm Bowel Dis. 2017;23:912–922.
   PubMed Web of Science ®Google Scholar
• Kozik AJ, Nakatsu CH, Chun H, et al. Comparison of the fecal, cecal, and mucus microbiome in male and female mice after TNBS-induced colitis. PLoS One. 2019;14:e0225079.
   PubMed Web of Science ®Google Scholar
• Reinoso Webb C, den Bakker H, Koboziev I, et al. Differential susceptibility to t cell-induced colitis in mice: role of the intestinal microbiota. Inflamm Bowel Dis. 2018;24:361–379.
   PubMed Web of Science ®Google Scholar
• Roy U, Gálvez EJC, Iljazovic A, et al. Distinct microbial communities trigger colitis development upon intestinal barrier damage via innate or adaptive immune cells. Cell Rep. 2017;21:994–1008.
   PubMed Web of Science ®Google Scholar
• Keubler LM, Buettner M, Häger C, et al. A multihit model: colitis lessons from the interleukin-10-deficient mouse. Inflamm Bowel Dis. 2015;21:1967–1975.
   PubMed Web of Science ®Google Scholar
• Kawaguchi-Miyashita M, Shimada S, Kurosu H, et al. An accessory role of TCRgammadelta (+) cells in the exacerbation of inflammatory bowel disease in TCRalpha mutant mice. Eur J Immunol. 2001;31:980–988.
   PubMed Web of Science ®Google Scholar
• Annese V, Valvano MR, Palmieri O, et al. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol. 2006;12:3636–3644.
   PubMed Web of Science ®Google Scholar
• Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127:26–40.
   PubMed Web of Science ®Google Scholar
• Leveille-Webster CR, Arias IM. The biology of the P-glycoproteins. J Membr Biol. 1995;143:89–102.
   PubMed Web of Science ®Google Scholar
• Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice. Am J Physiol Gastrointest Liver Physiol. 2005;289:G153–62.
   PubMed Web of Science ®Google Scholar
• Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733–5744.
   PubMed Web of Science ®Google Scholar
• Masunaga Y, Noto T, Suzuki K, et al. Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis. Inflamm Res. 2007;56:439–446.
   PubMed Web of Science ®Google Scholar
• Wilk JN, Bilsborough J, Viney JL. The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol Res. 2005;31:151–159.
   PubMed Web of Science ®Google Scholar
• Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity. 1995;3:171–174.
   PubMed Web of Science ®Google Scholar
• Ostanin DV, Bao J, Koboziev I, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296:G135–G146.
   PubMed Web of Science ®Google Scholar
• Morrissey PJ, Charrier K. Induction of wasting disease in SCID mice by the transfer of normal CD4+/CD45RBhi T cells and the regulation of this autoreactivity by CD4+/CD45RBlo T cells. Res Immunol. 1994;145:357–362.
   PubMedGoogle Scholar
• Pavlick KP, Ostanin DV, Furr KL, et al. Role of T-cell-associated lymphocyte function-associated antigen-1 in the pathogenesis of experimental colitis. Int Immunol. 2006;18:389–398.
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203:2473–2483.
   PubMed Web of Science ®Google Scholar
• Perše M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012;2012:718617.
   PubMedGoogle Scholar
• Breynaert C, Dresselaers T, Perrier C, et al. Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn’s disease. PLoS One. 2013;8:e68876.
   PubMed Web of Science ®Google Scholar
• Creyns B, Cremer J, Hoshino T, et al. Fibrogenesis in chronic DSS colitis is not influenced by neutralisation of regulatory T cells, of major T helper cytokines or absence of IL-13. Sci Rep. 2019;9:10064.
   PubMed Web of Science ®Google Scholar
• Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1328–G1338.
   PubMed Web of Science ®Google Scholar
• Silva I, Pinto R, Mateus V. Preclinical study in vivo for new pharmacological approaches in inflammatory bowel disease: a systematic review of chronic model of TNBS-induced colitis. J. Clin. Med. 2019;8:3411574.
   Web of Science ®Google Scholar
• Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-β1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol. 2007;178:5859–5870.
   PubMed Web of Science ®Google Scholar
• Alex P, Zachos NC, Nguyen T, et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009;15:341–352.
   PubMed Web of Science ®Google Scholar
• Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–195.
   PubMed Web of Science ®Google Scholar
• Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68(1): 25–39.
   PubMed Web of Science ®Google Scholar
• Krug SM, Bojarski C, Fromm A, et al. Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis. Mucosal Immunol. 2018;11:345–356.
   PubMed Web of Science ®Google Scholar
• Lee C-M, He CH, Nour AM, et al. IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat Commun. 2016;7:12752.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Clin Pract Gastroenterol Hepatol. 2019;16:185–196.
   Google Scholar
• Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol. 1997;158:2099–2106.
   PubMed Web of Science ®Google Scholar
• Wang C, Hanly EK, Wheeler LW, et al. Effect of α4β7 blockade on intestinal lymphocyte subsets and lymphoid tissue development. Inflamm Bowel Dis. 2010;16:1751–1762.
   PubMed Web of Science ®Google Scholar
• Lindebo Holm T, Poulsen SS, Markholst H, et al. Pharmacological evaluation of the SCID T cell transfer model of colitis: as a model of Crohn’s disease. Int J Inflam. 2012;2012:412178.
   PubMedGoogle Scholar
• Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993;92:372–380.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368.
   PubMed Web of Science ®Google Scholar
• Soendergaard C, Seidelin JB, Steenholdt C, et al. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol. 2018;5:e000208.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15:229–239.e5.
   PubMed Web of Science ®Google Scholar
• Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2. Structure. 2010;18:332–342.
   PubMed Web of Science ®Google Scholar
• Chen W, Sivaprasad U, Tabata Y, et al. IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice. J Immunol. 2009;183:7870–7876.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Joshi B, Yang Z, et al. IL-13Ralpha2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut. 2014;63:1728–1736.
   PubMed Web of Science ®Google Scholar
• Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490–1497.
   PubMed Web of Science ®Google Scholar
• Fuss IJ. Treatment of ulcerative colitis with infliximab: are we there yet? J Pediatr Gastroenterol Nutr. 2004;38:247–249.
   PubMed Web of Science ®Google Scholar
• Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002;17:629–638.
   PubMed Web of Science ®Google Scholar
• Okamura M, Yoh K, Ojima M, et al. Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis. Exp Anim. 2014;63:133–140.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol. 2007;178:5859–5870.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Kesselring R, Martin M, et al. IL-13 orchestrates resolution of chronic intestinal inflammation via phosphorylation of glycogen synthase kinase-3beta. J Immunol. 2014;192:3969–3980.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70:748–756.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Boughton-Smith NK, Whittle BJ, et al. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Gut. 1992;33:513–517.
   PubMed Web of Science ®Google Scholar
• Whittle BJ, Varga C, Berko A, et al. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol. 2008;153:983–991.
   PubMed Web of Science ®Google Scholar
• Roberts WG, Simon TJ, Berlin RG, et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology. 1997;112:725–732.
   PubMed Web of Science ®Google Scholar
• Kashani A, Schwartz DA. The expanding role of anti-IL-12 and/or anti-IL-23 antibodies in the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2019;15:255–265.
   PubMedGoogle Scholar
• Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281–1290.
   PubMed Web of Science ®Google Scholar
• Castro-Mejía J, Jakesevic M, Krych Ł, et al. Treatment with a monoclonal anti-IL-12p40 antibody induces substantial gut microbiota changes in an experimental colitis model. Gastroenterol Res Pract. 2016;2016:4953120.
   PubMed Web of Science ®Google Scholar
• Maxwell JR, Zhang Y, Brown WA, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity. 2015;43:739–750.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111:1599–1607.
   PubMed Web of Science ®Google Scholar
• Eftychi C, Schwarzer R, Vlantis K, et al. Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment. Immunity. 2019;51:367–380 e4.
   PubMed Web of Science ®Google Scholar
• Hanžel J, D’Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2020;20:399–406.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158:537–549.e10.
   PubMed Web of Science ®Google Scholar
• Voelkl B, Vogt L, Sena ES, et al. Reproducibility of preclinical animal research improves with heterogeneity of study samples. PLoS Biol. 2018;16:e2003693.
   PubMed Web of Science ®Google Scholar
• Chateau T, Feakins R, Marchal-Bressenot A, et al. Histological remission in ulcerative colitis: under the microscope is the cure. Am J Gastroenterol. 2020;115:179–189.
   PubMed Web of Science ®Google Scholar
• Erben U, Loddenkemper C, Doerfel K, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557–4576.
   PubMed Web of Science ®Google Scholar
• Ryan FJ, Ahern AM, Fitzgerald RS, et al. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat Commun. 2020;11:1512.
   PubMed Web of Science ®Google Scholar
• Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016;14:20–32.
   PubMed Web of Science ®Google Scholar
• Barone M, Chain F, Sokol H, et al. A versatile new model of chemically induced chronic colitis using an outbred murine strain. Front Microbiol. 2018;9:565.
   Google Scholar
• Palamides P, Jodeleit H, Föhlinger M, et al. A mouse model for ulcerative colitis based on NOD-scid IL2R γnull mice reconstituted with peripheral blood mononuclear cells from affected individuals. Dis Model Mech. 2016;9:985–997.
   PubMed Web of Science ®Google Scholar
• Goettel JA, Kotlarz D, Emani R, et al. Low-dose interleukin-2 ameliorates colitis in a preclinical humanized mouse model. Cell Mol Gastroenterol Hepatol. 2019;8:193–195.
   PubMed Web of Science ®Google Scholar